Please login to the form below

Not currently logged in
Email:
Password:

EC gives nod to restless leg syndrome drug Targin

Mundipharma’s medicine is first opioid granted a licence for condition in the EU
mundipharma targin oxycodone naloxone restless legs syndrome

Mundipharma's Targin has been granted a licence in the EU for the treatment of restless leg syndrome (RLS).

It is the first opioid to be granted a licence in the EU for RLS, a neurological disorder characterised by an overwhelming urge to move, usually affecting the legs.

The approval covers the of the fixed combination of prolonged-release oxycodone/naloxone as a second line treatment for patients with severe to very severe idiopathic RLS, offered after the failure of dopaminergic therapy.

Dr Karen Reimer, managing director of Mundipharma, commented: “RLS can have a devastating impact on a patient's life. The manifestation of physical symptoms at night time can disturb sleep, which can lead to profoundly disruptive daytime fatigue, impaired concentration and even feelings of depression.

“This new indication for Targin provides a much needed new treatment options for people with RLS who are not gaining sufficient relief from their symptoms.”

The 12-week double blind, randomised placebo-controlled trial, which has a 40-week open-label extension, found that 42% of patients who took the combination were considered RLS remitters after 12 weeks compared to 19% in the placebo group.

At the end of the 40-week extension, 43% were considered remitters and 22% of those were considered asymptomatic by the International RLS Study Group severity rating scale.

Adverse effects noted in the study, occurring in less than one in ten of patients, included gastrointestinal disorders, headaches, drowsiness, fatigue, itching and excessive sweating.

Article by
Kirstie Pickering

12th January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics